Tumor microenvironment: barrier or opportunity towards effective cancer therapy
Tumor microenvironment (TME) is a specialized ecosystem of host components, designed
by tumor cells for successful development and metastasis of tumor. With the advent of 3D …
by tumor cells for successful development and metastasis of tumor. With the advent of 3D …
p53 signaling in cancer progression and therapy
The p53 protein is a transcription factor known as the" guardian of the genome" because of
its critical function in preserving genomic integrity. The TP53 gene is mutated in …
its critical function in preserving genomic integrity. The TP53 gene is mutated in …
Impact of oncogenic pathways on evasion of antitumour immune responses
S Spranger, TF Gajewski - Nature Reviews Cancer, 2018 - nature.com
Immunotherapeutic interventions are showing effectiveness across a wide range of cancer
types, but only a subset of patients shows clinical response to therapy. Responsiveness to …
types, but only a subset of patients shows clinical response to therapy. Responsiveness to …
[HTML][HTML] Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape
MD Wellenstein, KE de Visser - Immunity, 2018 - cell.com
Owing to their tremendous diversity and plasticity, immune cells exert multifaceted functions
in tumor-bearing hosts, ranging from anti-tumor to pro-tumor activities. Tumor immune …
in tumor-bearing hosts, ranging from anti-tumor to pro-tumor activities. Tumor immune …
T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection
Immunotherapies such as checkpoint-blocking antibodies and adoptive cell transfer are
emerging as treatments for a growing number of cancers. Despite clinical activity of …
emerging as treatments for a growing number of cancers. Despite clinical activity of …
[HTML][HTML] Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment
S Spranger - International immunology, 2016 - ncbi.nlm.nih.gov
Checkpoint blockade therapy has been proven to be highly active across many cancer types
but emerging evidence indicates that the therapeutic benefit is limited to a subset of patients …
but emerging evidence indicates that the therapeutic benefit is limited to a subset of patients …
Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment
L Yang, A Li, Q Lei, Y Zhang - Journal of hematology & oncology, 2019 - Springer
Immunotherapy is a currently popular treatment strategy for cancer patients. Although recent
developments in cancer immunotherapy have had significant clinical impact, only a subset …
developments in cancer immunotherapy have had significant clinical impact, only a subset …
Emerging role of PTEN loss in evasion of the immune response to tumours
Mutations in PTEN activate the phosphoinositide 3-kinase (PI3K) signalling network, leading
to many of the characteristic phenotypic changes of cancer. However, the primary effects of …
to many of the characteristic phenotypic changes of cancer. However, the primary effects of …
Exploiting tumor neoantigens to target cancer evolution: current challenges and promising therapeutic approaches
Immunotherapeutic manipulation of the antitumor immune response offers an attractive
strategy to target genomic instability in cancer. A subset of tumor-specific somatic mutations …
strategy to target genomic instability in cancer. A subset of tumor-specific somatic mutations …
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes
M Sobral-Leite, I Salomon, M Opdam, DT Kruger… - Breast Cancer …, 2019 - Springer
Introduction The presence of tumor-infiltrating lymphocytes (TILs) is correlated with good
prognosis and outcome after (immuno) therapy in triple-negative and HER2-positive breast …
prognosis and outcome after (immuno) therapy in triple-negative and HER2-positive breast …